卡博替尼或成晚期肾细胞癌骨转移患者新标准治疗:METEOR试验亚组分析
METEOR试验的预设亚组分析评估了卡博替尼对比依维莫司在晚期肾细胞癌骨转移患者中的疗效。骨转移患者中,卡博替尼组中位无进展生存期(PFS)为7.4个月 vs 2.7个月(HR 0.33,95%CI 0.21-0.51),中位总生存期(OS)为20.1个月 vs 12.1个月(HR 0.54,95%CI 0.34-0.84),客观缓解率(ORR)为17% vs 0%。卡博替尼在骨转移患者中显示出PFS、OS和ORR的改善,且安全性与非骨转移患者一致。
要点
- 骨转移患者中卡博替尼较依维莫司显著改善PFS(7.4 vs 2.7个月,HR 0.33)。
- 骨转移患者中卡博替尼较依维莫司显著改善OS(20.1 vs 12.1个月,HR 0.54)。
- 骨转移患者中卡博替尼ORR为17%,依维莫司为0%。
核心结论
- 在晚期肾细胞癌骨转移患者中,卡博替尼对比依维莫司改善了PFS、OS和ORR,是良好的治疗选择。
研究设计与样本
- 按基线骨转移状态(独立影像学委员会评估)进行亚组分析。
主要发现
- 骨转移患者中(卡博替尼n=77,依维莫司n=65),中位PFS为7.4个月 vs 2.7个月(HR 0.33,95%CI 0.21-0.51)。
- 骨转移患者中,中位OS为20.1个月 vs 12.1个月(HR 0.54,95%CI 0.34-0.84),ORR为17% vs 0%。
- 骨转移患者中,骨相关事件发生率为23% vs 29%,骨扫描缓解率为20% vs 10%。
- 无骨转移患者中,卡博替尼同样改善了PFS、OS和ORR。
- 卡博替尼组骨生物标志物变化大于依维莫司组,骨转移患者安全性与非骨转移患者一致。
关键数值与推荐
- 骨转移患者中卡博替尼中位PFS 7.4个月,依维莫司2.7个月(HR 0.33,95%CI 0.21-0.51)。
- 骨转移患者中卡博替尼中位OS 20.1个月,依维莫司12.1个月(HR 0.54,95%CI 0.34-0.84)。
- 骨转移患者中卡博替尼ORR 17%,依维莫司0%。
- 骨转移患者中卡博替尼骨相关事件率23%,依维莫司29%;骨扫描缓解率20% vs 10%。
临床怎么用
- 对于晚期肾细胞癌伴骨转移且既往接受过VEGFR靶向治疗的患者,卡博替尼可考虑作为治疗选择。
- 卡博替尼在骨转移患者中显示出PFS、OS和ORR的获益,且安全性可控。
局限性
- 为亚组分析,样本量有限(骨转移患者卡博替尼n=77,依维莫司n=65)。
- 骨相关事件和骨扫描缓解率为次要终点,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Cabozantinib, an inhibitor of tyrosine kinases including MET, vascular endothelial growth factor receptors, and AXL, increased progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in patients with advanced renal cell carcinoma (RCC) after previous vascular endothelial growth factor receptor-targeted therapy in the phase III METEOR trial. Because bone metastases are associated with increased morbidity in patients with RCC, bone-related outcomes were analyzed in METEOR. Patients and Methods Six hundred fifty-eight patients were randomly assigned 1:1 to receive 60 mg cabozantinib or 10 mg everolimus. Prespecified subgroup analyses of PFS, OS, and ORR were conducted in patients grouped by baseline bone metastases status per independent radiology committee (IRC). Additional end points included bone scan response per IRC, skeletal-related events, and changes in bone biomarkers. Results For patients with bone metastases at baseline (cabozantinib [n = 77]; everolimus [n = 65]), median PFS was 7.4 months for cabozantinib versus 2.7 months for everolimus (hazard ratio, 0.33 [95% CI, 0.21 to 0.51]). Median OS was also longer with cabozantinib (20.1 months v 12.1 months; hazard ratio, 0.54 [95% CI, 0.34 to 0.84]), and ORR per IRC was higher (17% v 0%). The rate of skeletal-related events was 23% with cabozantinib and 29% with everolimus, and bone scan response per IRC was 20% versus 10%, respectively. PFS, OS, and ORR were also improved with cabozantinib in patients without bone metastases. Changes in bone biomarkers were greater with cabozantinib than with everolimus. The overall safety profiles of cabozantinib and everolimus in patients with bone metastases were consistent with those observed in patients without bone metastases. Conclusion Cabozantinib treatment was associated with improved PFS, OS, and ORR when compared with everolimus treatment in patients with advanced RCC and bone metastases and represents a good treatment option for these patients.
引用
- Escudier B, Powles T, Motzer RJ, et al. Cabozantinib, a New Standard of Care for Patients With Advanced Renal Cell Carcinoma and Bone Metastases? Subgroup Analysis of the METEOR Trial. J Clin Oncol. 2018. PMID: 29309249. doi:10.1200/JCO.2017.74.7352
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。